Latest news with #Bio-RadLaboratories
Yahoo
29-05-2025
- Business
- Yahoo
Bio-Rad's Management to Host Investor Meetings During Jefferies Global Healthcare Conference
HERCULES, Calif., May 29, 2025--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company's Chief Operating Officer Jon DiVincenzo will host one-on-one meetings with investors during the Jefferies Global Healthcare Conference in New York City, on June 4, 2025. About Bio-Rad Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with over 7,500 employees, and $2.6 billion in revenues in 2024. Our customers include universities, research institutions, hospitals, and biopharmaceutical companies, as well as clinical, food safety and environmental quality laboratories. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit View source version on Contacts Investor Contact: Edward Chung, Investor Relations510-741-6104ir@ Media Contact: Anna Gralinska, Corporate Communications510-741-6643cc@ Sign in to access your portfolio
Business Wire
29-05-2025
- Business
- Business Wire
Bio-Rad's Management to Host Investor Meetings During Jefferies Global Healthcare Conference
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company's Chief Operating Officer Jon DiVincenzo will host one-on-one meetings with investors during the Jefferies Global Healthcare Conference in New York City, on June 4, 2025. Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with over 7,500 employees, and $2.6 billion in revenues in 2024. Our customers include universities, research institutions, hospitals, and biopharmaceutical companies, as well as clinical, food safety and environmental quality laboratories. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit
Business Wire
12-05-2025
- Business
- Business Wire
Bio-Rad's Management to Participate in Fireside Chat During 2025 RBC Capital Markets Global Healthcare Conference
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Executive Officer Norman Schwartz and Chief Financial Officer Roop K. Lakkaraju will participate in a fireside chat event during the 2025 RBC Capital Markets Global Healthcare Conference on Wednesday, May 21, 2025, at 1:35 PM Eastern Time (10:35 AM Pacific Time). A live webcast and subsequent replay of the event will be available in the Investor Relations section of Bio-Rad's website at About Bio-Rad Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with over 7,500 employees, and $2.6 billion in revenues in 2024. Our customers include universities, research institutions, hospitals, and biopharmaceutical companies, as well as clinical, food safety and environmental quality laboratories. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit
Yahoo
29-04-2025
- Business
- Yahoo
Bio-Rad Laboratories, Inc. (BIO): Among Billionaire Mason Hawkins' Small-Cap Stocks with Huge Upside Potential
We recently published a list of . In this article, we are going to take a look at where Bio-Rad Laboratories, Inc. (NYSE:BIO) stands against other billionaire Mason Hawkins' small-cap stocks with huge upside potential. Mason Hawkins is a prominent American investor, known for being the founder and chairman of Southeastern Asset Management. Hawkins holds a Bachelor of Arts in Finance from the University of Florida and later did his MBA in Finance from the University of Georgia. Before founding Southeastern Asset Management, the billionaire gained experience as a Director of Research at Atlantic National Bank and First Tennessee Investment Management. There he developed his value investment strategy and has since been known for his discipline in value investing. His fund Southeastern Asset Management also holds the same reputation, which can be witnessed through his concentrated portfolio of around 40 to 50 stocks. Southeastern Asset Management services 47 clients at the moment, with $5,271,901,660 as assets under management as of March 2024. Value investment is an investment strategy that employs buying stocks of well-managed and quality companies at prices significantly below their intrinsic value. The core of Hawkins' strategy is to purchase equities when their market price is no more than 60% of the firm's appraisal of their intrinsic value. Value investors believe that the market overreacts to economic news, which leads to movement in stock prices, however, this news does not affect the long-term fundamentals of a company. Therefore, investors like Mason Hawkins do not follow the herd and use financial research and analysis to find quality companies. Value investors are also known for holding companies for a long term, but also actively ferret out stock that the market is underestimating. Hawkins' disciplined and research-based investment strategy has earned him widespread recognition. He achieved Investor's Lifetime Achievement Award in 2005 and was also named Domestic Equity Fund Manager of the Year by Morningstar in 2006. Under the current market condition, Hawkins' value investment strategy has led Southeastern Asset Management's attention towards small-cap stocks. While the small-cap stocks have largely underperformed the market when compared to their large-cap counterparts. However, according to Francis Gannon, Co-Chief Investment Officer at Royce Investment Partners, small-caps are attractively priced for long-term investment opportunities. Gannon's investment advice aligns with Hawkins's strategy, as he suggests investing in quality small-cap companies with strong fundamentals, low debt, established long-term earnings, and significant upside potential. To compile the list of billionaire Mason Hawkins' 10 small-cap stocks with huge upside potential, we sifted through 13F filings of Southeastern Asset Management, from Insider Monkey. From these filings, we checked each stock's upside potential from CNN and ranked the stocks in ascending order of the upside potential. We have also added the stake Southeastern Asset Management holds in each company and the hedge fund sentiment around each stock. Please note that the data was recorded on April 28, 2025. Also note that for this article we have defined small-cap companies as those with a market capitalization between $1 billion to $10 billion. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (). A laboratory at Gencaro performing a cardiovascular study with the rNAPc2 protein. Bio-Rad Laboratories, Inc. (NYSE:BIO) medical technology company that engages in developing and marketing a range of life science research and clinical diagnostic products. It operates through two main segments including the Life Science and Clinical Diagnostic segments. Its products range from testing kits to informatics systems and other key technologies such as chromatography, electrophoresis, flow cytometry, and more. On April 2, RBC Capital analyst Conor McNamara maintained a Buy rating on the stock with a price target of $430. The company is focusing on enhancing its product portfolio. On February 13, Bio-Rad Laboratories, Inc. (NYSE:BIO) announced the acquisition of Stilla Technologies to enhance its digital PCR capabilities. Management noted that Stilla's Nio dPCR systems complement existing QX Droplet Digital PCR and QX Continuum platforms, and will help broaden automation capabilities. The company based softness in the fiscal fourth quarter of 2024. Its total revenue declined 2% year-over-year along with gross margins, which fell from 53.8% to 51.2%. To manage the losses Bio-Rad Laboratories, Inc. (NYSE:BIO) has decided to cut 5% of the workforce to save around $50 million to $55 million in 2025. Looking ahead, management anticipates 1.5% to 3.5% revenue growth in 2025. It is one of the billionaire Mason Hawkins' 10 small-cap stocks with huge upside potential. Overall, BIO ranks 4th on our list of billionaire Mason Hawkins' small-cap stocks with huge upside potential. While we acknowledge the potential of BIO as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than BIO but that trades at less than 5 times its earnings, check out our report about this . READ NEXT: and . Disclosure: None. This article is originally published at . Sign in to access your portfolio
Yahoo
22-04-2025
- Business
- Yahoo
Does Bio-Rad Laboratories (BIO) Offer a Solid Financial Profile?
Ariel Investments, an investment management company, released its 'Ariel Appreciation Fund' first-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the first quarter, investors fled to shelter as hopes for another year of U.S. outperformance, driven by economic momentum and the new administration's pro-business approach swiftly gave way to tariff fears and policy uncertainty, causing most of the major U.S. indices to close the quarter in the red. Against this backdrop, the fund returned -6.94% in the first quarter underperforming the Russell Midcap Value Index's -2.11% returns, and the Russell Midcap Index's -3.40% returns. In addition, please check the fund's top five holdings to know its best picks in 2025. In its first-quarter 2025 investor letter, Ariel Appreciation Fund highlighted stocks such as Bio-Rad Laboratories, Inc. (NYSE:BIO). Bio-Rad Laboratories, Inc. (NYSE:BIO) is a life science company that manufactures and distributes life science research and clinical diagnostic products. The one-month return of Bio-Rad Laboratories, Inc. (NYSE:BIO) was -4.22%, and its shares lost 16.97% of their value over the last 52 weeks. On April 21, 2025, Bio-Rad Laboratories, Inc. (NYSE:BIO) stock closed at $236.88 per share with a market capitalization of $6.691 billion. Ariel Appreciation Fund stated the following regarding Bio-Rad Laboratories, Inc. (NYSE:BIO) in its Q1 2025 investor letter: "Alternatively, manufacturer and developer of laboratory equipment and biological testing, Bio-Rad Laboratories, Inc. (NYSE:BIO), declined over the period after the National Institutes of Health (NIH) announced significant cuts to its internal funding structure. Management also issued disappointing guidance on continued softness in the biopharma and academic research segments as well as uncertainty in the funding environment. Despite the challenging backdrop, we believe the company offers a solid financial profile, including recurring revenue streams and rising operating profit margins." A research scientist in a lab wearing safety glasses, surrounded by laboratory equipment testing life science samples. Bio-Rad Laboratories, Inc. (NYSE:BIO) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 42 hedge fund portfolios held Bio-Rad Laboratories, Inc. (NYSE:BIO) at the end of the fourth quarter which was 38 in the previous quarter. While we acknowledge the potential of Bio-Rad Laboratories, Inc. (NYSE:BIO) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. In another article, we covered Bio-Rad Laboratories, Inc. (NYSE:BIO) and shared Longleaf Partners Fund's views on the company. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
